Ireland’s Minister for Health has published a consultation paper on overhauling the nation’s approach to biosimilar medicines. The paper indicates that the Irish government is developing a National Biosimilar Medicines Policy “to promote the rational use of biosimilar medicines and to create a sustainable environment for biological medicines in Ireland.”
Ireland’s Minister for Health has published a consultation paper on overhauling the nation’s approach to biosimilar medicines. The paper indicates that the Irish government is developing a National Biosimilar Medicines Policy “to promote the rational use of biosimilar medicines and to create a sustainable environment for biological medicines in Ireland.”
The consultation paper highlights the fact that only 11 biosimilars are currently reimbursable by the state’s healthcare system, while over €200 million (approximately $235 million) is spent each year on biologic drugs that already have approved biosimilars or that will have available biosimilars by 2018.
Currently, Ireland’s Health Products Regulatory Authority supports physician-led switching of biologics and biosimilars, but stresses that any change in prescribing should be made in consultation with the patient. However, the health authority discourages repeated switches and prohibits automatic substitution with biosimilars at the pharmacy level. Looking forward, the paper indicates that Ireland should consider the following policies and how they have affected biosimilar uptake in the European Union (EU) in order to inform its own approach to the drugs:
Prescribing
Education
Incentives and Disincentives
Tendering and Pricing
Preventing Inappropriate Business Practices
Publication of the consultation paper follows a Department of Public Expenditure report, published in May, that urged the Irish government to make substantial changes to its policies in order to rein in drug spending. The paper explained that the Irish government spends €2 billion per year (approximately $2.36 billion), or 15% of its total healthcare expenditure, on drugs. That number is only expected to grow as new, high-cost drugs continue to dominate the healthcare marketplace; the paper cited an estimated 3% annual growth in drug spending until 2020.
The report also noted that Ireland has one of the lowest biosimilar adoption levels in Europe, across both EU- and non-EU states. With only a 15% uptake for biosimilar granulocyte colony-stimulating factor, Ireland was second only to Belgium in terms of the smallest market share for biosimilars.
The Irish Department of Health is holding a public comment period on the consultation paper through September 22, 2017.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.